Hospice Of Northeastern Michigan 830 S Otsego Ave, Gaylord, MI, 49735 | |
(989) 358-4280 |
News Archive
Genesis Biopharma, Inc., a biotechnology company developing targeted cancer therapies, and Lonza, today announced the signing of a process development and scale-up agreement relating to the manufacture of Contego™, Genesis Biopharma's autologous cell therapy product candidate for the treatment of Stage IV metastatic melanoma.
In 2 articles published this week in PLOS Medicine, Saskia van der Kam of Médecins Sans Frontières (MSF) and colleagues describe the outcomes of two randomised controlled trials in resource-limited settings to determine if the vicious cycle between childhood illness and malnutrition could be broken with a brief period of food supplementation during recovery from illness.
China Medical Technologies, Inc., a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic products, today announced that the Company has received approval for its Leukemia BCR/ABL fusion gene detection FISH Probe (the "Leukemia BCR/ABL FISH Probe") from the State Food and Drug Administration of China (the "SFDA").
The third quarter of 2009 has followed the same pattern as previous years, with low demand during the summer months and clinics closed for the summer. Production at the end of the quarter has been high with high demand at our clinics.
› Verified 4 days ago
Name | Hospice Of Northeastern Michigan |
---|---|
Location | 830 S Otsego Ave, Gaylord, Michigan |
Hospice ID | 231536 |
Category | Freestanding Hospice |
Ownership Type | Voluntary Non-profit - Private |
Profit Type | NON-PROFIT |
Accreditation Provider | Community Health Accreditation Partner (CHAP) |
SSA county code | 680 |
News Archive
Genesis Biopharma, Inc., a biotechnology company developing targeted cancer therapies, and Lonza, today announced the signing of a process development and scale-up agreement relating to the manufacture of Contego™, Genesis Biopharma's autologous cell therapy product candidate for the treatment of Stage IV metastatic melanoma.
In 2 articles published this week in PLOS Medicine, Saskia van der Kam of Médecins Sans Frontières (MSF) and colleagues describe the outcomes of two randomised controlled trials in resource-limited settings to determine if the vicious cycle between childhood illness and malnutrition could be broken with a brief period of food supplementation during recovery from illness.
China Medical Technologies, Inc., a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic products, today announced that the Company has received approval for its Leukemia BCR/ABL fusion gene detection FISH Probe (the "Leukemia BCR/ABL FISH Probe") from the State Food and Drug Administration of China (the "SFDA").
The third quarter of 2009 has followed the same pattern as previous years, with low demand during the summer months and clinics closed for the summer. Production at the end of the quarter has been high with high demand at our clinics.
› Verified 4 days ago
Quality Measure | Provider Score | National Score |
---|---|---|
Patients or caregivers who were asked about treatment preferences like hospitalization and resuscitation at the beginning of hospice care | 100.0 | 98.3 |
Patients or caregivers who were asked about their beliefs and values at the beginning of hospice care | 99.8 | 93.6 |
Patients who were checked for pain at the beginning of hospice care | 100.0 | 93.9 |
Patients who got a timely and thorough pain assessment when pain was identified as a problem | 69.4 | 77.7 |
Patients who were checked for shortness of breath at the beginning of hospice care | 100.0 | 97.3 |
Patients who got timely treatment for shortness of breath | 100.0 | 94.6 |
Patients taking opioid pain medication who were offered care for constipation | 99.5 | 93.3 |
News Archive
Genesis Biopharma, Inc., a biotechnology company developing targeted cancer therapies, and Lonza, today announced the signing of a process development and scale-up agreement relating to the manufacture of Contego™, Genesis Biopharma's autologous cell therapy product candidate for the treatment of Stage IV metastatic melanoma.
In 2 articles published this week in PLOS Medicine, Saskia van der Kam of Médecins Sans Frontières (MSF) and colleagues describe the outcomes of two randomised controlled trials in resource-limited settings to determine if the vicious cycle between childhood illness and malnutrition could be broken with a brief period of food supplementation during recovery from illness.
China Medical Technologies, Inc., a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic products, today announced that the Company has received approval for its Leukemia BCR/ABL fusion gene detection FISH Probe (the "Leukemia BCR/ABL FISH Probe") from the State Food and Drug Administration of China (the "SFDA").
The third quarter of 2009 has followed the same pattern as previous years, with low demand during the summer months and clinics closed for the summer. Production at the end of the quarter has been high with high demand at our clinics.
› Verified 4 days ago
Home Health Aides | 11.6 |
Counselors | 6.6 |
Medical Social Workers | 4 |
Physicians | 0.25 |
Registered Nurses | 14.6 |
Other Personnel | 9 |
Total Employees | 46.05 |
---|
News Archive
Genesis Biopharma, Inc., a biotechnology company developing targeted cancer therapies, and Lonza, today announced the signing of a process development and scale-up agreement relating to the manufacture of Contego™, Genesis Biopharma's autologous cell therapy product candidate for the treatment of Stage IV metastatic melanoma.
In 2 articles published this week in PLOS Medicine, Saskia van der Kam of Médecins Sans Frontières (MSF) and colleagues describe the outcomes of two randomised controlled trials in resource-limited settings to determine if the vicious cycle between childhood illness and malnutrition could be broken with a brief period of food supplementation during recovery from illness.
China Medical Technologies, Inc., a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic products, today announced that the Company has received approval for its Leukemia BCR/ABL fusion gene detection FISH Probe (the "Leukemia BCR/ABL FISH Probe") from the State Food and Drug Administration of China (the "SFDA").
The third quarter of 2009 has followed the same pattern as previous years, with low demand during the summer months and clinics closed for the summer. Production at the end of the quarter has been high with high demand at our clinics.
› Verified 4 days ago
Hospice Of Northeastern Michigan Location: 830 S Otsego Ave, Gaylord, Michigan, 49735 Phone: (989) 358-4280 |